Studies of body composition and fat distribution in HIV-infected and control subjects.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Studies of body composition and fat distribution in HIV-infected and control subjects.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):228-37. Unique Identifier : AIDSLINE MED/99174788
Kotler DP; Rosenbaum K; Wang J; Pierson RN; Department of Medicine, St. Luke's-Roosevelt Hospital Center,; Columbia University College of Physicians and Surgeons, New York,; New York 10025, USA.

Abstract: OBJECTIVE: Recent studies have documented alterations in body fat distribution that have been associated with protease inhibitor therapy. We compared body composition, including measurements of fat distribution, in 96 HIV-infected subjects studied since January 1996 (current HIV), subjects seen prior to January 1996 (previous HIV), and healthy controls. DESIGN: Retrospective cross-sectional studies of subjects matched by gender, race, age, and height. METHODS: Body weight, height, body cell mass by whole-body counting of 40K plus fat, fat-free mass, and body fat distribution by anthropometry were measured. RESULTS: Current HIV men weighed more (p = .025) and had more body cell mass than previous HIV men, but less than controls (p < .001). In women, the between group differences in fat were greater than the differences in body cell mass. Current and previous HIV study subjects had lower indices of subcutaneous and higher indices of visceral fat than controls. In current HIV subjects, body fat distribution was significantly associated with log plasma HIV RNA content but not with antiretroviral or protease inhibitor usage, nor with CD4+ lymphocyte counts. In 7 of 9 current HIV subjects studied, 24-hour urinary free cortisol excretion was abnormally high. CONCLUSIONS: Alterations in body fat distribution are a characteristic feature in HIV infection. The occurrence of increased visceral fat content and decreased subcutaneous fat content preceded the era of combination antiretroviral therapy. The alteration in fat distribution may be affected by plasma HIV RNA content rather than antiretroviral or protease-inhibitor therapy. The body composition alterations might be associated with endogenous hypercortisolism.

Keywords: JOURNAL ARTICLE Adult Anti-HIV Agents/PHARMACOLOGY *Body Composition Cross-Sectional Studies Fats/*METABOLISM Female Human Hydrocortisone/METABOLISM HIV Infections/DRUG THERAPY/METABOLISM/*PHYSIOPATHOLOGY HIV Protease Inhibitors/PHARMACOLOGY Male Retrospective Studies Support, U.S. Gov't, P.H.S. Time Factors
990630
A9960980

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .